Literature DB >> 23274355

Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.

Qi-Fa Liu1, Zhi-Ping Fan, Mei-Qing Wu, Jing Sun, Xiu-Li Wu, Dan Xu, Qian-Li Jiang, Yu Zhang, Fen Huang, Yong-Qiang Wei, Jie Zhao, Guo-Pan Yu, Fan-Yi Meng.   

Abstract

Knowledge concerning the clinical and biological characteristics of acute leukemia of ambiguous lineage (ALAL) is limited so that there has been a lack of uniformity in treatment. In this report, we retrospectively investigated the effect of intensified conditioning on adult ALAL undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 59 patients with ALAL (male in 37 cases and female in 22 cases) were consecutively enrolled in the data analyses. Twenty-four patients received the standard conditioning (total body irradiation (TBI) + cyclophosphamide (CY) or busulfan + CY protocol) and 35 received the intensified conditioning (TBI + CY + etoposide or fludarabine + cytarabine plus TBI + CY + etoposide protocol). Five-year transplant-related mortality was 17.6 ± 9.6 % and 25.5 ± 8.0 %, the 5-year overall survival (OS) post-transplantation was 23.8 ± 8.9 % and 64.0 ± 8.4 %, disease-free survival was 16.7 ± 7.6 % and 55.8 ± 9.4 %, the 5-year cumulative incidence of relapse was 80.8 ± 8.5 % and 28.8 ± 9.9 %, respectively, in the standard and the intensified group (P = 0.380, P = 0.029, P = 0.005, and P < 0.001). Both univariate and multivariate analysis indicated that the intensified conditioning regimen and acute graft-versus-host disease were favorable factors to reduce the relapse. The younger patients, patients with CR at the time of transplantation, and the intensified conditioning regimen were favorable factors to elevate the survival. In conclusion, intensified conditioning regimens followed by allo-HSCT might improve long-term survival and decrease relapse of leukemia in adult ALAL compared to the standard conditioning regimens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23274355     DOI: 10.1007/s00277-012-1662-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  13 in total

1.  Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia.

Authors:  Reinhold Munker; Ruta Brazauskas; Hai Lin Wang; Marcos de Lima; Hanna J Khoury; Robert Peter Gale; Richard T Maziarz; Brenda M Sandmaier; Daniel Weisdorf; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-21       Impact factor: 5.742

2.  Treatment of acute mixed-cell leukemia with autologous hematopoietic SCT followed by allogeneic hematopoietic stem cell micro-transplantation.

Authors:  Y-S Chen; X-J Kong; X-H Zhang; X-L Yin
Journal:  Bone Marrow Transplant       Date:  2014-04-14       Impact factor: 5.483

3.  Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study.

Authors:  Hua Jin; Zhiping Fan; Fen Huang; Yanyan Chai; Li Xuan; Ren Lin; Na Xu; Jieyu Ye; Jing Sun; Qifa Liu
Journal:  Infection       Date:  2019-02-07       Impact factor: 3.553

4.  Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.

Authors:  Bartlomiej M Getta; Mikhail Roshal; Junting Zheng; Jae H Park; Eytan M Stein; Ross Levine; Esperanza B Papadopoulos; Ann A Jakubowski; Nancy A Kernan; Peter Steinherz; Richard J O'Reilly; Miguel-Angel Perales; Sergio A Giralt; Martin S Tallman; Brian C Shaffer
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-08       Impact factor: 5.742

Review 5.  The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.

Authors:  Lanping Xu; Hu Chen; Jing Chen; Mingzhe Han; He Huang; Yongrong Lai; Daihong Liu; Qifa Liu; Ting Liu; Ming Jiang; Hanyun Ren; Yongping Song; Zimin Sun; Jianmin Wang; Depei Wu; Daobin Zhou; Ping Zou; Kaiyan Liu; Xiaojun Huang
Journal:  J Hematol Oncol       Date:  2018-03-02       Impact factor: 17.388

6.  Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia.

Authors:  Sandipkumar H Patel; Sumithira Vasu; Ling Guo; Olivia Lemaster; John C Byrd; Alison Walker
Journal:  J Natl Compr Canc Netw       Date:  2020-01       Impact factor: 11.908

7.  Haploidentical Transplantation Without In Vitro T-Cell Depletion Results in Outcomes Equivalent to Those of Contemporaneous Matched Sibling and Unrelated Donor Transplantation for Acute Leukemia.

Authors:  Sijian Yu; Qian Fan; Jing Sun; Zhiping Fan; Yu Zhang; Qianli Jiang; Fen Huang; Li Xuan; Min Dai; Hongsheng Zhou; Hui Liu; Qi-Fa Liu
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

8.  Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used.

Authors:  Alan Pomerantz; Sergio Rodriguez-Rodriguez; Roberta Demichelis-Gomez; Georgina Barrera-Lumbreras; Olga Barrales-Benitez; Xavier Lopez-Karpovitch; Alvaro Aguayo-Gonzalez
Journal:  Blood Res       Date:  2016-12-23

Review 9.  Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation.

Authors:  Meng Lv; Ying-Jun Chang; Xiao-Jun Huang
Journal:  Bone Marrow Transplant       Date:  2019-08       Impact factor: 5.483

10.  Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT.

Authors:  Reinhold Munker; Myriam Labopin; Jordi Esteve; Christoph Schmid; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.